FDA Modernization Act 3.0

# FDA Modernization Act 3.0 Summary **What the Bill Would Do** The FDA Modernization Act 3.0 (HR 2821) aims to update how the Food and Drug Administration operates. While specific details aren't provided in this summary, "modernization" bills of this type typically propose changes to FDA processes for approving drugs, medical devices, and food products. These changes often focus on speeding up approval timelines, updating outdated regulations, or adjusting how the agency evaluates safety and effectiveness. **Who It Affects** This bill would primarily impact pharmaceutical and medical device companies (through potentially faster approval processes), healthcare providers, patients seeking access to new treatments, and FDA staff who implement these regulations. The general public would be affected indirectly through changes in drug availability and food safety oversight. **Current Status** As of now, the bill remains in committee, meaning it has not yet been debated or voted on by the full House of Representatives.

It was introduced by Rep. Buddy Carter (R-GA), so it hasn't advanced beyond the initial committee review stage. To learn the specific provisions being proposed, you would need to review the full bill text on Congress.gov.